SARS-CoV-2 Antibodies

Cross-source consensus on SARS-CoV-2 Antibodies from 1 sources and 5 claims.

1 sources · 5 claims

Evidence quality

Severe fatigue was not associated with anti-SARS-CoV-2 antibody levels at 12 or 24 months. — Prevalence of severe fatigue after SARS-CoV-2 infection in Norway: a prospective 2-year follow-up study
The study measured spike antibodies quantitatively using the Elecsys Anti-SARS-CoV-2 S assay. — Prevalence of severe fatigue after SARS-CoV-2 infection in Norway: a prospective 2-year follow-up study
The study measured nucleocapsid antibodies qualitatively using the Elecsys Anti-SARS-CoV-2 assay. — Prevalence of severe fatigue after SARS-CoV-2 infection in Norway: a prospective 2-year follow-up study
Antibody levels were divided into high and low groups because their distributions were heavily skewed. — Prevalence of severe fatigue after SARS-CoV-2 infection in Norway: a prospective 2-year follow-up study
Long-term antibody response differences appear unlikely to explain post-COVID-19 syndrome prevalence. — Prevalence of severe fatigue after SARS-CoV-2 infection in Norway: a prospective 2-year follow-up study